OMALIZUMAB
omalizumab 300 mg/2 mL injection, 2 mL pen device
OMALIZUMAB (14895Y)
14895Y
Manner of administration:Injection
Restriction
Indication: Severe chronic spontaneous urticaria
Treatment phase: Initial treatment
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 1 | # of repeats: 2 | DPMQ: $418.14 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Xolair | |||||